Protagonist Obtains Third Patent for Therapy Targeting a Bowel Disease-related Protein
News
Protagonist Therapeutics has obtained a U.S. patent for an inflammatory bowel disease treatment that is in clinical trials. PTG-100 inhibits a protein known as alpha-4-beta-7 integrin that is associated with IBDs. Scientists consider it one ... Read more